@article{b478ccdbd6b34fc09b5fd352c60072f1,
title = "ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population",
abstract = "Background and Objectives: ABO blood group may affect risk of SARS-CoV-2 infection and/or severity of COVID-19. We sought to determine whether IgG, IgA and neutralizing antibody (nAb) to SARS-CoV-2 vary by ABO blood group. Materials and Methods: Among eligible convalescent plasma donors, ABO blood group was determined via agglutination of reagent A1 and B cells, IgA and IgG were quantified using the Euroimmun anti-SARS-CoV-2 ELISA, and nAb titres were quantified using a microneutralization assay. Differences in titre distribution were examined by ABO blood group using non-parametric Kruskal–Wallis tests. Adjusted prevalence ratios (aPR) of high nAb titre (≥1:160) were estimated by blood group using multivariable modified Poisson regression models that adjusted for age, sex, hospitalization status and time since SARS-CoV-2 diagnosis. Results: Of the 202 potential donors, 65 (32%) were blood group A, 39 (19%) were group B, 13 (6%) were group AB, and 85 (42%) were group O. Distribution of nAb titres significantly differed by ABO blood group, whereas there were no significant differences in anti-spike IgA or anti-spike IgG titres by ABO blood group. There were significantly more individuals with high nAb titre (≥1:160) among those with blood group B, compared with group O (aPR = 1·9 [95%CI = 1·1–3·3], P = 0·029). Fewer individuals had a high nAb titre among those with blood group A, compared with group B (aPR = 0·6 [95%CI = 0·4-1·0], P = 0·053). Conclusion: Eligible CCP donors with blood group B may have relatively higher neutralizing antibody titres. Additional studies evaluating ABO blood groups and antibody titres that incorporate COVID-19 severity are needed.",
keywords = "ABO group, COVID-19, SARS-CoV-2, convalescent plasma, titre",
author = "Bloch, {Evan M.} and Patel, {Eshan U.} and Christi Marshall and Kirsten Littlefield and Ruchika Goel and Grossman, {Brenda J.} and Winters, {Jeffrey L.} and Ruchee Shrestha and Imani Burgess and Oliver Laeyendecker and Shmuel Shoham and David Sullivan and Gehrie, {Eric A.} and Redd, {Andrew D.} and Quinn, {Thomas C.} and Arturo Casadevall and Andrew Pekosz and Tobian, {Aaron A.R.}",
note = "Funding Information: This work was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) AI052733 and AI15207 (A.C.); NIAID R01AI120938, R01AI120938S1 and R01AI128779 (A.A.R.T); NIAID T32AI102623 (E.U.P.); the Division of Intramural Research, NIAID, NIH (O.L., A.R., T.Q.); National Heart Lung and Blood Institute 1K23HL151826-01 (E.M.B) and R01HL059842 (A.C.), Bloomberg Philanthropies (A.C.); Department of Defense W911QY2090012 (D.S.). We are grateful to all participants who enrolled in this study and donated plasma. We thank the National Institute of Infectious Diseases, Japan, for providing VeroE6TMPRSS2 cells and acknowledge the Centers for Disease Control and Prevention, BEI Resources, NIAID, NIH for SARS-related coronavirus 2, Isolate USA-WA1/2020, NR-5228. EMB, EUP and AART were responsible for study conception, oversight, analysis and writing the first draft of the manuscript. CM and KL conducted antibody testing. RS and IB conducted donor screening. AP, RG, BJG, JLW, OL, SS, DS, EAG, ADD, TCQ, AC and AP provided input on laboratory testing and data analysis. All contributed to editing the manuscript. Funding Information: This work was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) AI052733 and AI15207 (A.C.); NIAID R01AI120938, R01AI120938S1 and R01AI128779 (A.A.R.T); NIAID T32AI102623 (E.U.P.); the Division of Intramural Research, NIAID, NIH (O.L., A.R., T.Q.); National Heart Lung and Blood Institute 1K23HL151826‐01 (E.M.B) and R01HL059842 (A.C.), Bloomberg Philanthropies (A.C.); Department of Defense W911QY2090012 (D.S.). Publisher Copyright: {\textcopyright} 2021 International Society of Blood Transfusion",
year = "2021",
month = aug,
doi = "10.1111/vox.13070",
language = "English",
volume = "116",
pages = "766--773",
journal = "Vox sanguinis",
issn = "0042-9007",
number = "7",
}